206. Fragile X syndrome Clinical trials / Disease details
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-000251-89-BE (EUCTR) | 22/10/2014 | 18/08/2014 | A clinical study with an investigational drug called ganaxolone in children with fragile X syndrome | A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome - GNX study | behavioral problems in children with fragile X syndrome MedDRA version: 17.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316 INN or Proposed INN: GANAXOLONE | Antwerp University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 60 | United States;Belgium |